Go to Amigdalina Home Page

 

 

 

Deprenyl in Alzheimer's Disease

 

Return to Cyto Pharma

Alzheimer and Parkinson are both neurodegenerative diseases, several studies have been conducted to demonstrate the effects of Deprenyl on Alzheimer's. The brain is not composed of discrete compartments; it is an organ of interdependent parts. The question arose whether Deprenyl, by improving the tone of the dopaminergic system, might not be useful in treating other neurodegenerative diseases.

Alzheimer's disease, for example, seemed to be the result of brain damage in regions removed from the dopaminergic system. Slowing the progression of a degenerative disease would itself tend to prolong life. Deprenyl through an psychostimulant effect caused by the release of more dopamine, increase life expectancy8.

In the aging brain there is a loss of neurons compensated for by a proliferation of glial cells. Because of the increased B-type monoamine oxidase activity present in the ganglia, "dopaminergic and trace aminergic", modulation in the brain declines in senescence.

The significant increase of the incidence of depression in the elderly, the age-dependent decline in male sexual vigor and the frequent appearance of parkinsonian symptoms in the latter decades of life might be attributed to a decrease of dopamine and trace amines in the brain. The outlines of a drug strategy counteract these biochemical lesions of aging by chronic administration

of Deprenyl, a selective inhibitor of B type monoamine oxidase, which facilitates dopaminergic and trace-aminergic activity in the brain, are forwarded 30,31.

The restitution and long term maintenance of full scale sexual activity in aged male rats continuously treated with (-)Deprenyl and the clinical observation that this drug prolongs in a statistically significant manner, the duration of the Parkinson's disease support the view that Deprenyl may improve deteriorating functions due to dopamine deficiency in the aging brain12.

amigdalina@cytopharma.com